Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic polymorphisms in ADRB1, ADRB2 and CYP2D6 genes and response to beta-blockers in patients with acute coronary syndrome.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 31 Dec 2023

Castaño-Amores Celia, Antúnez-Rodríguez Alba, Pozo-Agundo Ana, García-Rodríguez Sonia, Martínez-González Luis Javier, Dávila-Fajardo Cristina Lucía

Abstract excerpt

Betablockers (BBs) are prescribed for ischaemia in patients with acute coronary syndrome (ACS). In Spain, bisoprolol and carvedilol are the most prescribed BBs, but patients often had to discontinue them due to adverse effects. Single nucleotide polymorphisms (SNPs) in ADRB1, ADRB2 and CYP2D6 genes have strong evidence of pharmacogenetic association with BBs in heart failure or hypertension, but the evidence in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Coronary Syndrome
Share to Adrenergic beta-Antagonists

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Hypotension

Share to Percutaneous Coronary Intervention

Share to Polymorphism, Single Nucleotide

Share to Receptors, Adrenergic, beta-1

Share to Receptors, Adrenergic, beta-2

Source

Identifiers

PMID: 37952358
DOI: 10.1016/j.biopha.2023.115869

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic polymorphisms in ADRB1, ADRB2 and CYP2D6 genes and response to beta-blockers in patients with acute coronary syndrome.PMID 37952358Read ↗

Pharmacogenetic polymorphisms affecting bisoprolol response.Semantic proximity Read ↗

Assessment of ADRB1 polymorphism in patients with acute coronary syndrome treated with ticagrelor and aspirin.Semantic proximity Read ↗

Association of beta-1 and beta-2 adrenergic receptor gene polymorphisms with myocardial infarction.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy.Semantic proximity Read ↗

β-Adrenergic Receptor Gene Polymorphisms and β-Blocker Treatment Outcomes in HypertensionSemantic proximity Read ↗

Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome.Semantic proximity Read ↗

Association of common polymorphisms in β1-adrenergic receptor with antihypertensive response to carvedilol.Semantic proximity Read ↗

Pharmacogenetic factors affecting β-blocker metabolism and response.Semantic proximity Read ↗

β-Adrenergic receptor gene polymorphism is a genetic risk factor for cardiovascular disease: a cohort study with hypertensive patients.Semantic proximity Read ↗

Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to β-blocker therapy in hypertension.Semantic proximity Read ↗

Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking β-blockers.Semantic proximity Read ↗

The Association of ADRB1 and CYP2D6 Polymorphisms With Antihypertensive Effects and Analysis of Their Contribution to Hypertension Risk.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.